NEW YORK (GenomeWeb News) — Sigma-Aldrich has paid Sangamo BioSciences a $1 million milestone as part of a deal for Sangamo to develop zinc finger nuclease reagents for the research market, Sangamo said this week.
The payment was a production milestone under an agreement the companies made in July 2007.
ZFNs can be designed to target any gene in any organism, Sangamo said, and can be used to rapidly make precise changes to a cell's characteristics
David Smoller, president of Sigma-Aldrich's Research Biotech business, said in a statement that the reagent platform, which it will market, will provide researchers with "the ability to precisely manipulate the genome of living cells, resulting in cell lines or whole organisms with defined gene deletions, insertions, or corrections."